MX2019004830A - Composiciones farmaceuticas y usos de ellas. - Google Patents
Composiciones farmaceuticas y usos de ellas.Info
- Publication number
- MX2019004830A MX2019004830A MX2019004830A MX2019004830A MX2019004830A MX 2019004830 A MX2019004830 A MX 2019004830A MX 2019004830 A MX2019004830 A MX 2019004830A MX 2019004830 A MX2019004830 A MX 2019004830A MX 2019004830 A MX2019004830 A MX 2019004830A
- Authority
- MX
- Mexico
- Prior art keywords
- substantially spherical
- microspheres
- num
- polymer
- api
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004005 microsphere Substances 0.000 abstract 4
- 239000007972 injectable composition Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las realizaciones de la presente invención se refieren a una pluralidad de microesferas sustancialmente esféricas que comprenden por lo menos un API sustancialmente dispersado en por lo menos un polímero y un lioprotector sobre una superficie exterior de la pluralidad de microesferas sustancialmente esféricas, en donde la pluralidad de microesferas sustancialmente esféricas tiene un diámetro de las partículas de D99[num] menor de 10 m; un valor de circularidad de D90[num] de 0,8 a 1,0; y comprenden un API de un peso del 20 al 40% en peso del polímero. tras realizaciones se relacionan con composiciones inyectables que comprenden dichas microesferas y métodos para tratar numerosas condiciones administrando dichas composiciones inyectables a un sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/059544 WO2018080521A1 (en) | 2016-10-28 | 2016-10-28 | Pharmaceutical compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019004830A true MX2019004830A (es) | 2019-08-05 |
| MX376523B MX376523B (es) | 2025-03-07 |
Family
ID=57256478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004830A MX376523B (es) | 2016-10-28 | 2016-10-28 | Composiciones farmacéuticas y usos de ellas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10925883B2 (es) |
| EP (1) | EP3515404B1 (es) |
| JP (1) | JP6712003B2 (es) |
| KR (1) | KR102135537B1 (es) |
| CN (3) | CN110099677A (es) |
| AU (1) | AU2016428204B2 (es) |
| CA (1) | CA3042009C (es) |
| ES (1) | ES2784522T3 (es) |
| IL (1) | IL266205B (es) |
| MX (1) | MX376523B (es) |
| PH (1) | PH12019500947B1 (es) |
| WO (1) | WO2018080521A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3515404B1 (en) | 2016-10-28 | 2020-03-18 | Spinethera | Pharmaceutical compositions and uses thereof |
| WO2020236950A1 (en) * | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing charged polymers |
| CN110123779A (zh) * | 2019-05-30 | 2019-08-16 | 山东谷雨春生物科技有限公司 | 一种用于关节腔内注射的微球及其制备方法 |
| WO2021011723A1 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis hydantoin compounds and related compositions and methods |
| CN111407744B (zh) * | 2020-01-19 | 2022-04-08 | 绍兴文理学院元培学院 | 一种枸橼酸托法替布长效缓释微球的制备方法 |
| CN114796126B (zh) * | 2022-04-02 | 2023-04-18 | 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) | 关节腔注射用硫酸羟氯喹缓释微球及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3491075B2 (ja) * | 1992-07-24 | 2004-01-26 | 武田薬品工業株式会社 | 微粒子製剤およびその製造法 |
| JP3191004B2 (ja) * | 1995-12-15 | 2001-07-23 | 武田薬品工業株式会社 | マイクロスフェアの製造法 |
| US6193951B1 (en) | 1997-04-30 | 2001-02-27 | Point Biomedical Corporation | Microparticles useful as ultrasonic contrast agents |
| WO2000030698A1 (en) | 1998-11-20 | 2000-06-02 | University Of Connecticut | Apparatus and method for control of tissue/implant interactions |
| US20030099682A1 (en) | 1998-11-20 | 2003-05-29 | Francis Moussy | Apparatus and method for control of tissue/implant interactions |
| MXPA03010679A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Una composicion para acelerar la cicatrizacion de fractura osea. |
| US20060204548A1 (en) * | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
| US7758778B2 (en) | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| KR20090116494A (ko) * | 2008-05-07 | 2009-11-11 | 가톨릭대학교 산학협력단 | 폴리-락티드-코-글리콜라이드 미립구, 그 제조방법, 및그것을 포함하는 단백질 또는 펩티드 약물 제제 |
| US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| DK2509634T3 (en) * | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| TR201818858T4 (tr) | 2010-01-04 | 2019-01-21 | Mapi Pharma Ltd | Glati̇ramer asetat i̇çeren depo si̇stemi̇. |
| GB2485886A (en) | 2010-11-24 | 2012-05-30 | Lithera Inc | Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction |
| WO2012110886A1 (en) * | 2011-02-16 | 2012-08-23 | Sanzyme Limited | Controlled-release formulation comprising hcg |
| US9423335B2 (en) | 2011-07-21 | 2016-08-23 | Invitrox, Inc. | Instrument and method for optical particle sensing |
| BR112014013033B1 (pt) | 2011-12-09 | 2019-12-03 | Unilever Nv | composição microbicida, método não-terapêutico para fornecer um efeito microbicida à pele e uso nãoterapêutico de uma composição |
| US8927529B2 (en) * | 2012-01-30 | 2015-01-06 | SpineThera | Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer |
| CA2908910C (en) | 2013-04-16 | 2021-03-02 | Unilever Plc | Liquid soap having enhanced antibacterial activity |
| EP3099773B2 (en) | 2014-01-29 | 2020-07-22 | Unilever NV | Cleansing composition containing oligodynamic metal and efficacy enhancing agent |
| EP3515404B1 (en) | 2016-10-28 | 2020-03-18 | Spinethera | Pharmaceutical compositions and uses thereof |
-
2016
- 2016-10-28 EP EP16794174.9A patent/EP3515404B1/en active Active
- 2016-10-28 CN CN201680091189.7A patent/CN110099677A/zh active Pending
- 2016-10-28 US US16/343,642 patent/US10925883B2/en active Active
- 2016-10-28 JP JP2019529880A patent/JP6712003B2/ja active Active
- 2016-10-28 CN CN202111429195.8A patent/CN114146057A/zh active Pending
- 2016-10-28 KR KR1020197015121A patent/KR102135537B1/ko active Active
- 2016-10-28 CN CN202311462789.8A patent/CN117503709A/zh active Pending
- 2016-10-28 WO PCT/US2016/059544 patent/WO2018080521A1/en not_active Ceased
- 2016-10-28 CA CA3042009A patent/CA3042009C/en active Active
- 2016-10-28 PH PH1/2019/500947A patent/PH12019500947B1/en unknown
- 2016-10-28 ES ES16794174T patent/ES2784522T3/es active Active
- 2016-10-28 AU AU2016428204A patent/AU2016428204B2/en active Active
- 2016-10-28 MX MX2019004830A patent/MX376523B/es active IP Right Grant
-
2019
- 2019-04-23 IL IL266205A patent/IL266205B/en active IP Right Grant
-
2020
- 2020-12-23 US US17/247,820 patent/US11771707B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190084998A (ko) | 2019-07-17 |
| EP3515404B1 (en) | 2020-03-18 |
| BR112019008493A2 (pt) | 2019-07-09 |
| PH12019500947B1 (en) | 2023-08-09 |
| AU2016428204A1 (en) | 2019-06-13 |
| IL266205A (en) | 2019-05-30 |
| AU2016428204B2 (en) | 2019-09-26 |
| IL266205B (en) | 2020-05-31 |
| US20210186988A1 (en) | 2021-06-24 |
| US10925883B2 (en) | 2021-02-23 |
| CN117503709A (zh) | 2024-02-06 |
| EP3515404A1 (en) | 2019-07-31 |
| US20190269698A1 (en) | 2019-09-05 |
| JP6712003B2 (ja) | 2020-06-17 |
| JP2019533716A (ja) | 2019-11-21 |
| WO2018080521A1 (en) | 2018-05-03 |
| US11771707B2 (en) | 2023-10-03 |
| ES2784522T3 (es) | 2020-09-28 |
| PH12019500947A1 (en) | 2019-12-02 |
| MX376523B (es) | 2025-03-07 |
| KR102135537B1 (ko) | 2020-07-17 |
| CN114146057A (zh) | 2022-03-08 |
| CA3042009C (en) | 2020-05-19 |
| CA3042009A1 (en) | 2018-05-03 |
| CN110099677A (zh) | 2019-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004830A (es) | Composiciones farmaceuticas y usos de ellas. | |
| IL262581B1 (en) | Production methods, preparations and medical applications of drugs containing cannabis for oral administration | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| MX392548B (es) | Método para preparar microesferas biodegradables que tienen estabilidad mejorada y estabilidad en el almacenamiento. | |
| PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
| BR112015005940A2 (pt) | processo para a preparação de nanopartículas terapêuticas | |
| CL2016002308A1 (es) | Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer | |
| HK1246173A1 (zh) | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 | |
| BR112018071155A2 (pt) | formas de dosagem de antagonista opioide de liberação modificada | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| BR112017009545B8 (pt) | Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária | |
| UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| MX390100B (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
| MX2018005384A (es) | Composiciones y metodos para fabricar microparticulas de proteina. | |
| MX387005B (es) | Nanocápsula para la administración de un compuesto lipófilo y proceso de preparación de la misma. | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| MX2015012048A (es) | Un agente de soporte. | |
| JOP20200004B1 (ar) | تركيبات طويلة المفعول | |
| CR20170142A (es) | Composiciones farmacéuticas resistentes al abuso | |
| UY35824A (es) | Preparación farmacéutica y forma de su producción y uso | |
| BR112016027653A2 (pt) | Uso de uma partícula para absorver e reter compostos odoríferosos | |
| MX2017015812A (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
| MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |